4Filed Aug 31, 8:00 PM ET
Quoin (QNRX) CEO Michael Myers Buys ADSs and Warrants
$QNRX · Quoin Pharmaceuticals, Ltd.Research Summary
AI-generated summary of this SEC filing
Quoin (QNRX) CEO Michael Myers Buys ADSs and Warrants
What Happened
Michael Myers, CEO of Quoin Pharmaceuticals (QNRX), participated in a private placement on 2026-08-31, acquiring 20,490 American Depositary Shares (ADSs) at a combined price of $4.88 per ADS (totaling $99,991). As part of the same private placement he received 10,245 accompanying warrants (50% warrant coverage). The ADSs and warrants were issued together at the $4.88 combined purchase price. Each ADS represents 35 ordinary shares (so 20,490 ADSs equal 717,150 ordinary shares).
Key Details
- Transaction date: 2026-08-31; Form 4 filed: 2026-09-01 (timely)
- Purchase: 20,490 ADSs @ $4.88 each — total reported consideration $99,991
- Derivative received: 10,245 warrants issued with the ADSs (price N/A on Form 4)
- Shares owned after transaction: not specified in the Form 4 filing
- Relevant footnotes:
- F1: Each ADS = 35 ordinary shares (20,490 ADSs = 717,150 ordinary shares)
- F2: ADSs purchased in private placement with 50% warrant coverage; ADSs and warrants issued at combined $4.88 price
- F3: Warrants are exercisable immediately upon issuance, subject to a beneficial ownership cap
- F4: Warrants expire on the earlier of (i) five years from issuance or (ii) 30 days after Quoin publicly announces the primary endpoint has been met in the CL-QRX003-004 trial for Netherton Syndrome
- Filing timeliness: Form appears timely (filed the business day after the transaction)
Context
- This was a purchase (management buying securities), which many investors view as a more informative signal than routine sales; it reflects a CEO participation in a company financing rather than a market open-market buy.
- The 10,245 instruments are warrants (derivative rights to buy ADSs) issued alongside the ADSs; they are not newly issued ordinary shares until exercised. Warrants are exercisable immediately but are subject to ownership limits and specific expiry conditions tied to trial outcomes or time.
- No indication in the filing that shares were sold or that this was a cashless exercise; this was a straightforward private placement purchase with attached warrants.